Salarius Pharmaceuticals, Inc. Price & Performance (SLRX)

Salarius Pharmaceuticals, Inc. experienced a dramatic rise in short interest during February, with shares sold short increasing by 724% from mid-month figures. This surge reflects heightened bearish sentiment among investors. Despite this, the company’s stock showed a modest recovery, trading up 3.8% recently, though it remains near its 52-week low of $0.90.1

Salarius Pharmaceuticals announced a registered offering of shares worth $417,000, aiming to bolster its capital. The move follows a challenging period for the company, which has seen its stock price fall significantly. This strategy aligns with its ongoing efforts to support drug development initiatives and strengthen its financial position.2

Salarius Pharmaceuticals’ stock has plunged to a 52-week low, reflecting broader market pressures and challenges in the biotech sector. Despite a healthy financial position, the company faces investor skepticism. Recent initiatives, including a clinical trial resumption and a merger with Decoy Therapeutics, aim to revitalize its growth prospects.3